Adenosine Receptors and Adenylate Cyclase Interactions

  • Constantine Londos
  • J. Wolff
  • Dermot M. F. Cooper
Part of the Developments in Pharmacology book series (DIPH, volume 2)


For many years it has been known that adenosine, at low concentrations, initiates numerous metabolic actions in a variety of cells. Although adenosine effects may result from altered purine metabolism [1, 2], some persist under conditions where the nucleoside is prevented from entering cells. Thus, a number of metabolic effects of adenosine persist or are enhanced in the presence of adenosine transport inhibitors, such as dipyridamole and nitrobenzylthioguanosine. These include inhibition of lipolysis in fat cells [3], inhibition of platelet aggregation [4], increased steroid production [5], potentiation of histamine release from mast cells [6], inhibition of vas deferens contraction [7], and coronary vasodilation [8]. Moreover, conjugates of adenosine with large molecules that are thought not to enter cells mimic the actions of free adenosine, the potency of adenosine in the conjugates being similar to that of the free nucleoside [3, 9–12]. Such findings gave birth to the notion that cells contain surface receptors for adenosine.


Adenylate Cyclase Adenosine Receptor Adenosine Deaminase Leydig Cell Tumor Adenosine Receptor Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fox IH, Kelly WN: The role of adenosine and 2′-deoxy-adenosine in mammalian cells. Annu Rev Biochem 47: 655–686, 1978.PubMedCrossRefGoogle Scholar
  2. 2.
    Arch JRS, Newsholme EA: The control of the metabolism and the hormonal role of adenosine. Essays Biochem 14: 82–123, 1978.PubMedGoogle Scholar
  3. 3.
    Fain JN, Malbon CC: Regulation of adenylate cyclase by adenosine. Mol Cell Biochem 23: 1–27, 1979.Google Scholar
  4. 4.
    Haslam RJ, Rosson GM: Effects of adenosine on levels of adenosine cyclic 3′, 5′-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 11: 528–544, 1975.PubMedGoogle Scholar
  5. 5.
    Wolff J, Cook GH: Activation of steroidogenesis and adenyl ate cyclase by adenosine in adrenal and Leydig tumor cells. J Biol Chem 252: 687–693, 1977.PubMedGoogle Scholar
  6. 6.
    Marquardt DL, Parker CE, Sullivan TJ: Potentiation of mast cell mediator release by adenosine. J Immunol 120: 871–878, 1978.PubMedGoogle Scholar
  7. 7.
    Muller MJ, Paton DM: Presynaptic inhibitory actions of 2-substituted adenosine derivative on neurotransmission in rat vas deferens: Effects of inhibitors of adenosine uptake and deamination. Arch Pharmacol 306: 23–28, 1979.CrossRefGoogle Scholar
  8. 8.
    Olsson RA, Snow JA, Gentry MK, Erick GP: Adenosine uptake by canine heart. Circ Res 31: 767–778, 1972.PubMedGoogle Scholar
  9. 9.
    Olsson RA, Davis CJ, Khouri EM, Patterson RE: Evidence for an adenosine receptor on the surface of dog coronary myocytes. Circ Res 39: 93–98, 1976.PubMedGoogle Scholar
  10. 10.
    Schrader J, Nees S, Gerlach E: Evidence for a cell surface adenosine receptor on coronary myocytes and atrial muscle cells. Pfluegers Arch 369: 251–257, 1977.CrossRefGoogle Scholar
  11. 11.
    Olsson RA, Davis CC, Khouri EM: Coronary vasoactivity of adenosine covalently linked to polylysine. Life Sci 21: 1343–1350, 1977.PubMedCrossRefGoogle Scholar
  12. 12.
    Okwuasaba FK, Hamilton JT, Cook MA: Evidence for the cell surface locus of presynaptic purine nucleotide receptors in the guinea pig ileum. J Pharmacal Exp Ther 207: 779–786, 1978.Google Scholar
  13. 13.
    Sattin A, Rall TW: The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′,5′-phosphate content of guinea pig cerebral cortex slices. Mol Pharmacol 6: 13–23, 1970.PubMedGoogle Scholar
  14. 14.
    Shimizu H, Daly JW: Formation of cyclic adenosine 3′, 5′ -monophosphate from adenosine in brain slices. Biochim Biophys Acta 222: 465–473, 1970.PubMedGoogle Scholar
  15. 15.
    Londos C, Wolff J, Cooper DMF: Adenosine as a regulator of adenyl ate cyclase, in Burnstock G (ed): Purinergic Receptors. London, Chapman and Hall, 1981, pp 287–323.Google Scholar
  16. 16.
    Wolff J, Londos C, Cooper DMF: Adenosine receptors and the regulation of adenylate cyclase. Adv Cyclic Nucleotide Res 14: 199–214, 1981.PubMedGoogle Scholar
  17. 17.
    Londos C, Wolff J, Cooper DMF: Action of adenosine on adenyl ate cyclase, in Baer HP, Drummond GI (eds): Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides. New York, Raven Press, 1979, pp 271–281.Google Scholar
  18. 18.
    Daly JW: Adenosine receptors: Targets for future drugs. J Med Chem 25: 197–207, 1982.PubMedCrossRefGoogle Scholar
  19. 19.
    Haslam RJ, Davidson MML, Lemmex BWG, Desjardins JV, McCarry BE: Adenosine receptors of the blood platelet: Interaction with adenylate cyclase, in Baer HP, Drummond GI (eds): Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides. New York, Raven Press, 1979, pp 189–204.Google Scholar
  20. 20.
    Trost T, Stock K: Effects of adenosine derivatives on cAMP accumulation and lipolysis in rat adipocytes and on adenyl ate cyclase in adipocyte plasma membranes. Arch Pharmacol 299: 33–40, 1977.CrossRefGoogle Scholar
  21. 21.
    Haslam RJ, Lynham JA: Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloroadenosine. Life Sci 11: 1143–1154, 1972.CrossRefGoogle Scholar
  22. 22.
    Sternweis PC, Northrup JK, Hanski E, Schleifer LS, Smigel MD, Gilman AG: Puriciation and properties of the regulatory component (G/F) of adenyl ate cyclase. Adv Cyclic Nucleotide Res 14: 23–36, 1981.PubMedGoogle Scholar
  23. 23.
    Rodbell M: The role of hormone receptors and GTP-regulatory proteins in hormone transduction. Nature 284: 17–22, 1980.PubMedCrossRefGoogle Scholar
  24. 24.
    Van Calker D, Muller M, Hamprecht B: Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 33: 999–1005, 1979.PubMedCrossRefGoogle Scholar
  25. 25.
    Londos C, Cooper DMF, Wolff J: Subclasses of adenosine receptors. Proc Natl Acad Sci USA 77: 2551–2554, 1980.PubMedCrossRefGoogle Scholar
  26. 26.
    Londos C, Wolff, J: Two distinct adenosine-sensitive sites on adenylate cyclase. Proc Natl Acad Sci USA 74: 5482–5485, 1977.PubMedCrossRefGoogle Scholar
  27. 27.
    Burnstock G: Past and current evidence for the purinergic nerve hypotheses, in Baer HP, Drummond GI (eds): Physiological and Regulatory Functions of Adenosine and Adenine Nucleotide. New York, Raven Press, 1979, pp 3–32.Google Scholar
  28. 28.
    Cooper DMF, Londos C: Evaluation of the effects of adenosine on hepatic and adipocyte adenylate cyclase under conditions where adenosine is not generated endogenously. J Cyclic Nucleotide Res 5: 289–302, 1979.PubMedGoogle Scholar
  29. 29.
    Rodbell M, Birnbaumer L, Pohl SL, Krans HM: The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver: An obligatory role of guanyl nucleotides in glucagon action. J Biol Chem 246: 1877–1882, 1971.PubMedGoogle Scholar
  30. 30.
    Londos C, Salomon Y, Lin MC, Harwood JP, Schramm M, Wolff J, Rodbell M: 5′-Guanylylimidodiphosphate, a potent activator of adenylate cyclase in eukaryotic cells. Proc Natl Acad Sci USA 71: 3087–3090, 1974.PubMedCrossRefGoogle Scholar
  31. 31.
    Lad PM, Nielsen TB, Londos C, Preston MS, Rodbell M: Independent mechanisms of adenosine activation and inhibition of the turkey erythrocyte adenyl ate cyclase system. J Biol Chem 255: 10841–10846, 1980.PubMedGoogle Scholar
  32. 32.
    Sevilla N, Tolkovsky AM, Levitzki A: Activation of turkey erythrocyte adenylate cyclase by two receptors: Adenosine and catecholamines. FEBS Lett 81: 339–341, 1977.PubMedCrossRefGoogle Scholar
  33. 33.
    Selinger Z, Cassel D: Role of guanine nucleotides in hormonal activation of adenylate cyclase. Adv Cyclic Nucleotide Res 14: 15–22, 1981.PubMedGoogle Scholar
  34. 34.
    Lad PM, Nielsen TB, Preston MS, Rodbell M: The role of the guanine nucleotide exchange reaction in the regulation of the β-adrenergic receptor and in the actions of catecholamines and cholera toxin on adenylate cyclase in turkey erythrocyte membranes. J Bioi Chem 255: 988–995, 1980.Google Scholar
  35. 35.
    Londos C, Cooper DMF, Rodbell M: Receptor-mediated stimulation and inhibition of adenylate cyclases: The fat cell as a model system. Adv Cyclic Nucleotide Res 14: 163–172, 1981.PubMedGoogle Scholar
  36. 36.
    Cooper DMF, Londos C: GTP-dependent stimulation and inhibition of adenylate cyclase, in Kohn LD (ed): Hormone Receptors. London, John Wiley, 1982, pp 309–333.Google Scholar
  37. 37.
    Jakobs KH, Aktories K, Schultz G: Inhibition of adenyl ate cyclase by hormones and neurotransmitters. Adv Cyclic Nucleotide Res 14: 173–188, 1981.PubMedGoogle Scholar
  38. 38.
    Londos C, Cooper DMF, Schlegel W, Rodbell M: Adenosine analogs inhibit adipocyte adenylase cyclase by a GTP-dependent process: Basis for actions of adenosine and methylxanthines on cyclic AMP production and lipolysis. Proc Natl Acad Sci USA 75: 5362–5366, 1978.PubMedCrossRefGoogle Scholar
  39. 39.
    Cooper DMF, Londos C, Rodbell M: Adenosine receptor-mediated inhibition of rat cerebral cortical adenylate cyclase by a GTP-dependent process. Mol Pharmacol 18: 598–601, 1980.PubMedGoogle Scholar
  40. 40.
    Cooper DMF, Schlegel W, Lin MC, Rodbell M: The fat cell adenylate cyclase system: Characterization and manipulation of its bimodal regulation by GTP. J Biol Chem 254: 8927–8931, 1979.PubMedGoogle Scholar
  41. 41.
    Guroff G, Dickens G, End D, Londos C: The action of adenosine analogs on PC12 cells. J Neurochem 37: 1431–1439, 1981.PubMedCrossRefGoogle Scholar
  42. 42.
    Fredholm BB: Are methylxanthine effects due to antagonism of endogenous adenosine? Trends Pharmacol Sci 1: 129–132, 1980.CrossRefGoogle Scholar
  43. 43.
    Smellie FW, Davis CW, Daly JW, Wells IN: Alkylxanthines: Inhibition of adenosine-elicited accumulation of cyclic AMP in brain slices and of brain phosphodiesterase activity. Life Sci 24: 2475–2482, 1979.PubMedCrossRefGoogle Scholar
  44. 44.
    Haslam RJ, Davidson MML, Desjardins JV: Inhibition of adenylate cyclase by adenosine analogues in preparation of broken and intact human platelets. Biochem J 176: 83–95, 1978.PubMedGoogle Scholar
  45. 45.
    Wolff J, Londos C, Cook GH: Adenosine interactions with thyroid adenylate cyclase. Arch Biochem Biophys 191: 161–168, 1978.PubMedCrossRefGoogle Scholar
  46. 46.
    Neer EJ, Salter RS: Reconstituted adenylate cyclase from bovine brain: Functions of the subunits. J BioI Chem 256: 10102–2107, 1981.Google Scholar
  47. 47.
    Premont J, Guillon G, Bockaert J: Specific Mg2+ and adenosine sites involved in a bireactant mechanism for adenylate cyclase inhibition and their probable localization on this enzyme’s catalytic component. Biochem Biophys Res Commun 90: 513–519, 1979.PubMedCrossRefGoogle Scholar
  48. 48.
    Green RD: Effects of exogenous adenosine deaminase and erythro-9-(2-Hydroxy-3-nonyl)adenine on intracellular cyclic AMP levels in Cl300 murine neuroblastoma in tissue culture. Lifo Sci 26: 399–406, 1980.CrossRefGoogle Scholar
  49. 49.
    Holgate ST, Lewis RA, Austen KF: Role of adenylate cyclase in immunologic release of mediators from rat mast cells: Agonist and antagonist effects of purine- and ribose-modified adenosine analogs. Proc Natl Acad Sci USA 77: 6800–6804, 1980.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague 1983

Authors and Affiliations

  • Constantine Londos
  • J. Wolff
  • Dermot M. F. Cooper

There are no affiliations available

Personalised recommendations